These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7958475)
61. Defective adenoviruses as virus vectors for veterinary vaccines. Eloit M Vet Res; 1995; 26(3):207-8. PubMed ID: 7795677 [No Abstract] [Full Text] [Related]
62. Capripoxvirus-based multivaccines. Black DN Dev Biol Stand; 1995; 84():179-82. PubMed ID: 7796952 [No Abstract] [Full Text] [Related]
63. [Quality control of the vaccines and cold chain during the national vaccination campaigns]. Couacy-Hymann E; Kodjo A; Ouattara M; Kanga K; Diawara S; Domenech J Rev Elev Med Vet Pays Trop; 1992; 45(2):129-33. PubMed ID: 1338738 [TBL] [Abstract][Full Text] [Related]
64. Production of veterinary vaccines in mammalian cell cultures. Sellers RF Lab Pract; 1970 Jan; 19(1):42-4. PubMed ID: 5416447 [No Abstract] [Full Text] [Related]
65. Uses of vaccinia virus in vaccine delivery. Ulaeto D; Hruby DE Curr Opin Biotechnol; 1994 Oct; 5(5):501-4. PubMed ID: 7765463 [TBL] [Abstract][Full Text] [Related]
66. Recombinant vaccinia viruses as vaccines. Brown F; Schild GC; Ada GL Nature; 1986 Feb 13-19; 319(6054):549-50. PubMed ID: 3945343 [TBL] [Abstract][Full Text] [Related]
67. The role of biotechnology in tropical diseases. Yilma T Ann N Y Acad Sci; 1992 Jun; 653():1-5. PubMed ID: 1626860 [No Abstract] [Full Text] [Related]
68. Susceptibility of exotic breeds of cattle to rinderpest lapinised and lapinised avianised vaccines. Dhanda MR; Uppal DR; Sharma GL Indian Vet J; 1967 Jan; 44(1):1-6. PubMed ID: 6066401 [No Abstract] [Full Text] [Related]
70. [Recombinant vaccinia viruses--the basis of new vaccines]. Vilcek S; Vrtiak OJ; Gdovinová A Cesk Epidemiol Mikrobiol Imunol; 1988 Mar; 37(2):73-9. PubMed ID: 2965621 [No Abstract] [Full Text] [Related]
71. The use of vaccinia virus for the construction of recombinant vaccines. Piccini A; Paoletti E Bioessays; 1986 Dec; 5(6):248-52. PubMed ID: 3551937 [No Abstract] [Full Text] [Related]
72. [Trends in research in developing new type of vaccines--aiming at efficacy and safety. HTLV vaccine]. Morita M Nihon Rinsho; 1987 Oct; 45(10):2437-43. PubMed ID: 2896259 [No Abstract] [Full Text] [Related]
73. Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Cole DJ; Wilson MC; Baron PL; O'Brien P; Reed C; Tsang KY; Schlom J Hum Gene Ther; 1996 Jul; 7(11):1381-94. PubMed ID: 8818725 [No Abstract] [Full Text] [Related]
74. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Jones L; Ristow S; Yilma T; Moss B Nature; 1986 Feb 13-19; 319(6054):543. PubMed ID: 3945341 [No Abstract] [Full Text] [Related]
75. Potential use of live viral and bacterial vectors for vaccines. WHO meeting, Geneva, 19-22 June, 1989. Vaccine; 1990 Oct; 8(5):425-37. PubMed ID: 2251869 [TBL] [Abstract][Full Text] [Related]
77. Veterinary vaccines. Specificities and the weight of regulations. Vannier P Vet Res; 1995; 26(3):194-7. PubMed ID: 7795671 [No Abstract] [Full Text] [Related]
78. The future of vaccinia. Dekking F Monogr Allergy; 1975; 9():187-95. PubMed ID: 1090806 [No Abstract] [Full Text] [Related]
79. Present and future applications of vaccinia virus as a vector. Hruby DE Vet Parasitol; 1988 Sep; 29(2-3):281-92. PubMed ID: 3059670 [TBL] [Abstract][Full Text] [Related]
80. [Molecular biology of vaccinia virus and development of a new type of vaccine]. Shida H Uirusu; 1986 Jun; 36(1):23-33. PubMed ID: 3535240 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]